Immunovia announced it is realigning its Swedish operations with its strategic priorities to drive R&D productivity and focus on the US commercialization of the IMMray™ PanCan-d test. In October 2022, Immunovia announced a research collaboration partnership with Proteomedix. The partnership capitalizes on the combined expertise of two leading innovators in proteomics-based diagnostics.

Following the early experience of the collaboration Immunovia has been able to better understand the opportunities available to the company and has determined that the in-house need for R&D capability has changed. As a result, Immunovia has initiated a union consultation process with the aim of reducing the number of employees within R&D and Operations in Lund. Immunovia has initiated a consultation process with relevant Swedish unions to create the best possible transition for the affected employees.

The Company will provide an update once the consultation process is concluded.